Sleep, Mood and Work Burden in 349 U.S. Adults With Atopic Dermatitis
Doctor’s Notes · Life in Motion · Evidence Review
Editorial disclosure: The featured scene is an AI-created illustration of a fictional work, home or research setting. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.
The question behind this paper
This review looks at adult work, sleep and mental-health burden. The aim is to preserve the study’s actual population, denominator, design and timepoint so a useful signal does not become a universal claim.
Study snapshot
| Study element | Reported detail |
|---|---|
| Population | 349 adults reporting atopic dermatitis in the 2013 U.S. National Health and Wellness Survey, matched to 698 controls |
| Design | Cross-sectional matched survey analysis |
| Timepoint | 2013 survey responses with current health and recent work/activity measures |
| Key result | Anxiety, depression and sleep-disorder reports were 29.8%, 31.2% and 33.2% versus 16.1%, 17.3% and 19.2%; absenteeism was 9.9% versus 3.6% and activity impairment 33.6% versus 25.2% |
How to interpret the result
The matched comparison shows that burden extends beyond visible skin. The percentages describe survey groups, not a forecast for an individual, and they cannot identify which clinical or workplace intervention would help.
Important limitation: Diagnoses and outcomes were self-reported, residual differences may remain after matching, and cross-sectional associations do not establish that AD caused each outcome.
Questionnaires, examinations, sensors, patch tests and administrative records answer different questions. A screening or monitoring result can guide the next step, but it does not diagnose the cause of one person’s rash. An association can identify a pattern worth investigating without proving that a single task, material or personal factor caused every event.
Questions a worker, family or clinician can ask next
- What exactly was measured: reported symptoms, visible signs, allergy, sleep movement, work loss or quality of life?
- Which denominator applies to the quoted percentage: everyone invited, respondents, symptomatic people, examined participants or a selectively tested subgroup?
- Did the study compare groups or follow change over time, and what factors could still explain the difference?
- Would clinician examination, occupational-health review or clinician-directed testing change the practical plan?
- What requires prompt medical evaluation, including rapidly spreading redness, drainage, fever, severe pain, breathing symptoms or major loss of function?
Primary and authoritative sources
- Primary medical research record: PubMed PMID 28606711
- Authoritative guidance relevant to this topic
- American Academy of Dermatology: eczema skin-care guidance
PubMed indexing is not NIH endorsement of a study’s interpretation, this article or any product.
Where a cosmetic moisturizer fits
Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003, and outside research does not become a product result. #003 is not an eczema medicine and this article makes no treatment, cure, prevention, pediatric-safety or 24-hour claim.
Bottom line
The responsible conclusion is narrow: keep the population, denominator, comparator, timepoint and limitations attached, then use the evidence to ask better clinical and exposure-control questions rather than promise a universal result.